Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on strong obesity drug momentum.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin analogs. Learn more about LLY stock here.

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli Lilly recently announced a significant partnership with Walmart to sell its popular weight-loss drug, Zepbound, at a discounted retail price through Walmart pharmacies.

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising full-year guidance.

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera.

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.